how glp 1 medications are changing consumer behavior Harvard Business Review | A PwC analysis shows that GLP-1 like Ozempic and Zepbound may be catalyzing a behavioral and economic shift on par with major GLP-1 Medications: Weight Loss &

To contextualise that number: the landmark STEP 1 trial of semaglutide 2.4 mg showed a mean weight loss of approximately 14.9%, and the SURMOUNT-1 trial of tirzepatide reached 20.9% at its highest dose [2, 3]

Store in the middle: Keep your pens or vials in the center of the refrigerator to avoid cold spots

Coverage decisions remain largely discretionary for self-funded plans, although fully insured employers may face additional requirements if states adopt mandates through insurance regulations

But rapid weight loss can temporarily raise uric acid and set off a gout flare in people who also have gout

The glucagon-like peptide-1 receptor in the ventromedial hypothalamus reduces short-term food intake in male mice by regulating nutrient sensor activity